Provided by Tiger Trade Technology Pte. Ltd.

Verrica Pharmaceuticals Inc.

6.73
-0.8200-10.86%
Post-market: 6.69-0.0400-0.59%17:43 EST
Volume:359.99K
Turnover:2.49M
Market Cap:63.87M
PE:-2.28
High:7.50
Open:7.29
Low:6.26
Close:7.55
52wk High:13.00
52wk Low:3.28
Shares:9.49M
Float Shares:1.94M
Volume Ratio:0.33
T/O Rate:18.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9552
EPS(LYR):-14.7812
ROE:-1546.58%
ROA:-26.28%
PB:-3.75
PE(LYR):-0.46

Loading ...

Verrica Pharmaceuticals CMO Noah L. Rosenberg Acquires Common Shares

Reuters
·
Nov 26

Director and 10% Owner Paul B. Manning Reports Acquisition of Verrica Pharmaceuticals Inc. Common Shares

Reuters
·
Nov 26

Verrica Pharmaceuticals CEO Jayson Rieger Reports Acquisition of Common Shares

Reuters
·
Nov 26

Interim CFO John J. Kirby Acquires Common Shares of Verrica Pharmaceuticals Inc

Reuters
·
Nov 26

BRIEF-Verrica Pharmaceuticals Enters Securities Purchase Agreement With Institutional Investors

Reuters
·
Nov 25

Verrica Pharmaceuticals Inc - Enters Securities Purchase Agreement With Institutional Investors - SEC Filing

THOMSON REUTERS
·
Nov 25

Verrica Pharmaceuticals Inc - to Sell 6.5 Mln Shares in Private Placement - SEC Filing

THOMSON REUTERS
·
Nov 25

Verrica Pharmaceuticals Raises $50 Million in Private Placement Financing

Reuters
·
Nov 24

Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway

THOMSON REUTERS
·
Nov 24

Lytix Biopharma reports promising clinical results for ruxotemitide in melanoma and basal cell carcinoma

Reuters
·
Nov 18

Verrica Pharmaceuticals reports $14.3 million revenue in third quarter 2025

Reuters
·
Nov 15

Verrica Pharmaceuticals Inc - Qtrly Net Loss per Share, Basic and Diluted $0.03

THOMSON REUTERS
·
Nov 15

Verrica Pharmaceuticals Q3 Income From Operations USD 1.627 Million

THOMSON REUTERS
·
Nov 15

Verrica Pharmaceuticals Reports Positive Phase 2 Results for VP-315 in Basal Cell Carcinoma

Reuters
·
Nov 10

Verrica Pharmaceuticals Presents New Data on Vp-315 From Its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40TH Society for Immunotherapy of Cancer Annual Meeting

THOMSON REUTERS
·
Nov 10

Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma

Reuters
·
Nov 10

Verrica Pharmaceuticals Inc expected to post a loss of 67 cents a share - Earnings Preview

Reuters
·
Oct 31

Verrica Pharmaceuticals Cleared to File for EU Approval of Molluscum Treatment

MT Newswires Live
·
Oct 21

Verrica Pharmaceuticals announces CHMP support for Ycanth MAA filing

TIPRANKS
·
Oct 21

BRIEF-Verrica Pharmaceuticals Receives Positive Feedback From The European Medicines Agency (EMA) Supporting A Clear Regulatory Path Forward To File For Approval Of Ycanth® In The European Union

Reuters
·
Oct 21